Sign in Subscribe

kras

A collection of 33 issues

Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions

Skip to content The CRC Digest Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions A prospective pilot study found that mucus collected from the colonoscope sheath during routine colonoscopy serves as a high-fidelity source of cell-free DNA for detecting KRAS-mutated colorectal neoplasia. (Translational Oncology) This content is informational only and

KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations

Skip to content The CRC Digest KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations RMC-8839, a covalent KRAS G13C inhibitor, induced tumor regressions in selected xenograft models, but one-third of cell lines showed incomplete pathway suppression, revealing that codon 13-mutant RAS differs from other KRAS mutations with decreased

CRC Research Update — June 20, 2026

Today's colorectal cancer research highlights

CDK4/6 inhibitor palbociclib targets β-catenin in KRAS-mutant tumors

Skip to content The CRC Digest CDK4/6 inhibitor palbociclib targets β-catenin in KRAS-mutant tumors Preclinical research identified palbociclib as an unexpected suppressor of β-catenin signaling that synergizes with KRAS or ERK5 inhibition in colorectal cancer models. (Journal of Translational Medicine) This content is informational only and does not constitute

CRC Research Finding

Skip to content The CRC Digest ◇ KRAS-mutant colorectal cancers show variable response to RAS inhibitors Preclinical research found that KRAS-mutant colorectal cancer models respond differently to RAS(ON) inhibitor RMC-7977 based on PI3K signaling and cyclin D1 expression patterns, with combined RAS and PI3K inhibition showing synergistic effects in some

CRC Research Update — June 18, 2026

Today's colorectal cancer research highlights

KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab

Skip to content The CRC Digest KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab A 57-year-old man with KRAS G13D-mutant metastatic rectal cancer and fluoropyrimidine intolerance achieved approximately 16.6 months of disease control with trifluridine/tipiracil plus bevacizumab integrated with liver-directed treatments,

CRC Research Update — June 06, 2026

Today's colorectal cancer research highlights

Novel SOS1 Inhibitors Show Potent Activity Against KRAS-Driven CRC

Skip to content The CRC Digest Novel SOS1 Inhibitors Show Potent Activity Against KRAS-Driven CRC Highly potent and selective SOS1 inhibitors disrupted the SOS1-KRAS interaction, inhibited nucleotide exchange in wild-type and multiple KRAS variants, and showed submicromolar anti-proliferative activity in colorectal cancer cells. (J Med Chem) This content is informational

CRC Research Update — June 04, 2026

Today's colorectal cancer research highlights